Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Department of Pediatrics, Division of Infectious Diseases, Seattle Children's Hospital and University of Washington, Seattle, Washington, USA.
J Pediatric Infect Dis Soc. 2021 Oct 27;10(9):926-929. doi: 10.1093/jpids/piab029.
Remdesivir is an RNA polymerase inhibitor that is commonly used in the treatment of patients with severe acute coronavirus disease 2019 (COVID-19). As the severe acute respiratory syndrome coronavirus 2 spreads, the use of remdesivir is likely to increase. Most of the patients treated with remdesivir will not experience any adverse events although some side effects have been reported. Here, we describe a case of sinus bradycardia associated with remdesivir therapy in a pediatric patient with severe acute COVID-19.
瑞德西韦是一种 RNA 聚合酶抑制剂,常用于治疗严重急性 2019 冠状病毒病(COVID-19)患者。随着严重急性呼吸综合征冠状病毒 2 的传播,瑞德西韦的使用可能会增加。虽然有报道称瑞德西韦治疗的部分患者出现了一些副作用,但大多数患者不会出现任何不良反应。在此,我们描述了一例严重急性 COVID-19 儿科患者在接受瑞德西韦治疗时出现窦性心动过缓的病例。